Search Results
Psychedelic-Assisted Therapies (PATs). The most empirically substantiated PAT for trauma incorporates an 18-session protocol that uses MDMA as the active agent in up to three separate sessions ( Mitchell et al., 2023 ). In addition, preliminary studies offer
spent gaming has been found to be higher among users of stimulants, methylenedioxymethamphetamine (MDMA), sedatives, and amphetamines. Turel and Bechara (2019) noted that moderate gamers had lower substance use, whereas excessive gamers had higher
decriminalization, groundbreaking legalization of therapeutic psilocybin, pending approval of MDMA for Post-Traumatic Stress Disorder (2003), and bills in progress legalizing personal possession and use, the expansion of psychotherapeutic approaches and applications
) analysis, he found that African Americans report unique motivations for using MDMA. However, he concedes that these results, obtained from a small, low socioeconomic (SES) sample, may not be representative. In his recommendations for further research, Rigg
psychedelic substances for the treatment of psychological disorders. This has included the administration of a range of substances, including LSD, psilocybin, ayahuasca, methylenedioxymethamphetamine (MDMA), and ibogaine, in conjunction with psychotherapy for
(broadly inclusive of psilocybin, lysergic-acid diethylamide [LSD], ketamine, and 3,4-Methylenedioxymethamphetamine [MDMA]) with psychotherapy could enhance intrinsic aspects related to recovery capital such as motivation, connectedness, self-efficacy and
, methamphetamines, heroin, prescription opioids, benzodiazepines, cocaine/crack, LSD, mescaline, mushrooms, DMT, salvia PCP, and MDMA (ecstasy). Perceived risk Participants were asked whether they had ever heard of
Introduction Psychedelic drugs like lysergic acid diethylamide (LSD-25), 3,4-methylenedioxymethamphetamine (MDMA), and psilocybin are being investigated again, showing therapeutic potential for certain psychological disorders
research indicates the potential of psychedelic-assisted therapy (PAT) to treat treatment-resistant mental disorders, including various substance use disorders ( Andersen, Carhart-Harris, Nutt, & Erritzoe, 2021 ). While atypical psychedelics (e.g., MDMA
treatment assignment can significantly influence both placebo and nocebo effects in psychedelic therapy. In a similar vein, Flameling, Aday, and Van Elk (2023) point out the potential for both placebo and nocebo effects in MDMA trials. It is described that
